首页> 外文期刊>BMC Urology >Standardised high dose versus low dose cranberry Proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol
【24h】

Standardised high dose versus low dose cranberry Proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol

机译:标准化的高剂量与低剂量的蔓越莓原花青素提取物在健康女性中的预防尿路复发[PACCANN]:双盲随机对照试验方案

获取原文
       

摘要

Urinary tract infections (UTIs) are amongst the most common bacterial infections affecting women. Although antibiotics are the treatment of choice for UTI, cranberry derived products have been used for many years to prevent UTIs, with limited evidence as to their efficacy. Our objective is to assess the efficacy of a cranberry extract capsule standardized in A-type linkage proanthocyanidins (PACs) for the prevention of recurrent urinary tract infection. We will perform a 1:1 randomized, controlled, double blind clinical trial in women aged 18?years or more who present ≥2 UTIs in 6?months or?≥?3 UTIs in 12?months. One hundred and forty-eight women will be recruited and randomized in two groups to either receive an optimal dose of cranberry extract quantified and standardized in PACs (2?×?18.5?mg PACs per day) or a control dose (2?×?1?mg PACs per day). The primary outcome for the trial is the mean number of new symptomatic UTIs in women during a 6-month intervention period. Secondary outcomes are: (1) To evaluate the mean number of new symptomatic UTIs with pyuria as demonstrated by a positive leucocyte esterase test; (2) To detect the mean number of new symptomatic culture-confirmed UTIs; (3) To quantify urinary PACs metabolites in women who take a daily dose of 37?mg PACs per day compared to women who take a daily dose of 2?mg per day for 6?months; (4) To characterize women who present recurrent UTI based on known risk factors for recurrent UTI; (5) To describe the side effects of daily intake of cranberry extract containing 37?mg PACs compared to 2?mg PACs. This report provides comprehensive methodological data for this randomized controlled trial. The results of this trial will inform urologists, gynaecologists, family physicians and other healthcare professionals caring for healthy women with recurrent UTI, as to the benefits of daily use of an optimal dose of cranberry extract for the prevention of recurrent UTI. Clinicaltrials.gov, identifier: NCT02572895 October 8th 2015.
机译:尿路感染(UTI)是影响妇女的最常见细菌感染之一。尽管抗生素是治疗UTI的选择,但蔓越莓衍生产品已被用于预防UTI多年,但其功效的证据有限。我们的目标是评估在A型连锁原花青素(PAC)中标准化的蔓越莓提取物胶囊对预防尿路反复感染的功效。我们将对18岁或以上的女性在6个月内出现≥2个UTI或在12个月内出现≥3个UTI的女性进行1:1随机对照双盲临床试验。一百四十八名妇女将被招募并随机分为两组,分别接受以PAC定量和标准化的最佳酸果蔓提取物剂量(每天2××18.5mg PAC)或对照剂量(2××?每天1?mg PAC)。该试验的主要结果是在6个月的干预期内妇女出现新症状的UTI的平均数。次要结果是:(1)通过阳性白细胞酯酶试验评估新的有脓尿症状的UTIs的平均数; (2)检测新的有症状文化确认的尿路感染的平均数; (3)与每天服用2毫克每天6个月的妇女相比,每天服用37毫克PACs的妇女定量尿中PAC代谢物; (4)根据已知的复发性尿路感染危险因素,对表现出复发性尿路感染的妇女进行特征分析; (5)描述每天摄入含有37?mg PAC的蔓越莓提取物相对于2?mg PAC的副作用。该报告为该随机对照试验提供了全面的方法学数据。该试验的结果将告知泌尿科医师,妇科医师,家庭医生和其他医疗保健专业人员,以照顾患有复发性UTI的健康女性,每天使用最佳剂量的蔓越莓提取物预防复发性UTI的益处。 Clinicaltrials.gov,标识符:NCT02572895,2015年10月8日。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号